ACE and coronary artery disorder: In addition, 410 (100.0%), 289 (70.5%), 116 (28.3%), 177 (43.2%), and 157 (38.3%) CHD patients received antiplatelet therapy, β-blocker, calcium channel blockers, statin or other lipid-lowering therapy, and angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB), respectively.